Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to $11.6 million.

  • Editas Medicine's Change in Accured Expenses fell 153.50% to -$543,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 1418.94%. This contributed to the annual value of $11.6 million for FY2024, which is 182.52% up from last year.
  • Per Editas Medicine's latest filing, its Change in Accured Expenses stood at $11.6 million for FY2024, which was up 182.52% from $4.1 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Change in Accured Expenses peaked at $11.6 million during FY2024, and registered a low of -$4.2 million during FY2021.
  • In the last 3 years, Editas Medicine's Change in Accured Expenses had a median value of $10.5 million in 2022 and averaged $8.7 million.
  • In the last 5 years, Editas Medicine's Change in Accured Expenses crashed by 128.29% in 2020 and then soared by 352.16% in 2022.
  • Editas Medicine's Change in Accured Expenses (Yearly) stood at -$2.7 million in 2020, then crashed by 55.27% to -$4.2 million in 2021, then spiked by 352.16% to $10.5 million in 2022, then plummeted by 60.84% to $4.1 million in 2023, then surged by 182.52% to $11.6 million in 2024.